Loading…
Pfizer Inc. is projected to rise to $31.85 by 2027, a +22% move from its current price of $26.21. PFE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $25.97 | $26.21 | $26.45 | +0.01% |
| May 30 | $25.87 | $26.21 | $26.56 | +0.01% |
| May 31 | $25.80 | $26.22 | $26.64 | +0.02% |
| Jun 1 | $25.74 | $26.22 | $26.71 | +0.03% |
| Jun 2 | $25.68 | $26.22 | $26.77 | +0.04% |
| Jun 3 | $25.64 | $26.22 | $26.82 | +0.04% |
| Jun 4 | $25.59 | $26.22 | $26.87 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $25.59 | $26.22 | $26.87 | +0.05% |
| Week 2 | $25.35 | $26.24 | $27.16 | +0.10% |
| Week 3 | $25.16 | $26.25 | $27.38 | +0.15% |
| Week 4 | $25.01 | $26.26 | $27.57 | +0.20% |
| Week 5 | $24.88 | $26.28 | $27.75 | +0.25% |
| Week 6 | $24.77 | $26.29 | $27.91 | +0.30% |
| Week 7 | $24.66 | $26.30 | $28.05 | +0.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pf Pfizer Inc. is a healthcare company that discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Its portfolio spans internal medicine products, vaccines, oncology, inflammation and immunology, rare disease therapies, biosimilars, and sterile injectables. Major brands and products include Eliquis, Paxlovid, the Prevnar family, Nurtec ODT/Vydura, Zavzpret, Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna, along with Inflectra, Retacrit, Ruxience, Zirabev, Trazimera, and Nivestym biosimilars.
Pfizer was founded in 1849 and is headquartered in New York, New York. It maintains collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models.
Pf Pfizer Inc. (PFE) is a healthcare stock with a current price of $25.90, a market cap of $147.62B, and a market rank of 102.
The near-term path shows limited drift, with the 2026 average price at $25.90 (min $25.15, max $34.80) and a 30-day price pattern ranging from $24.36 to $27.54. The longer horizon presents substantial upside, as the forecast elevates the 2030 average to $44.69 and the 2050 average to $201.70, with long-run ROIs reaching 72.5% by 2030 and 678.8% by 2050.
Overall, the data indicate a modest near-term price path but meaningful multi-year upside, supported by a bullish longer-term sentiment.
A major floor 7.9% below — a decisive break under it would weaken the trend.
The nearest floor, 3.4% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 9.1% above — clearing it would confirm fresh momentum.
Key PFE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PFE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $25.94 | Buy | $25.95 | Buy |
| MA 10 | $25.77 | Buy | $25.91 | Buy |
| MA 20 | $26.01 | Buy | $26.07 | Buy |
| MA 50 | $26.78 | Sell | $26.44 | Sell |
| MA 100 | $26.63 | Sell | $26.39 | Sell |
| MA 200 | $25.82 | Buy | $26.09 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.11 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 42.24 | Neutral |
| Williams %R (14) | -23.48 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 2.06 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 76.52 | Neutral |
| TRIX (15) | -0.19 | Sell |
| Awesome (5,34) | -0.51 | Sell |
| Ultimate (7,14,28) | 70.51 | Sell |
| Momentum (10) | 0.34 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 26.08 | Buy |
| ADX (14) | 15.36 | Neutral |
| ATR (14) | 0.22 | Info |
The 30-day range is $24.36 to $27.54. The current price is $25.90, sitting between support at $25.33 and resistance at $27.56.
The SMA50 is $26.81 and the SMA200 is $25.80. RSI14 is 40, indicating room to move higher without being overbought. The sentiment is BULLISH and the annualized volatility is 20%.
This setup suggests potential for a move toward the nearby resistance if momentum improves, though near-term upside may be limited while price remains near the stated support.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.15 | $26.21 | $35.08 | 0% | Neutral | |
| $26.02 | $31.85 | $40.81 | +22% | Bullish | |
| $31.50 | $39.26 | $51.62 | +50% | Bullish | |
| $34.03 | $43.05 | $57.78 | +64% | Bullish | |
| $34.76 | $44.57 | $60.88 | +70% | Bullish | |
| $38.65 | $50.16 | $69.58 | +91% | Bullish | |
| $39.21 | $51.46 | $72.38 | +96% | Bullish | |
| $40.71 | $53.98 | $76.91 | +106% | Bullish | |
| $48.80 | $65.34 | $94.19 | +149% | Bullish | |
| $54.29 | $73.38 | $106.94 | +180% | Bullish | |
| $68.03 | $95.89 | $146.41 | +266% | Bullish | |
| $130.92 | $197.87 | $323.77 | +655% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $25.15 | $26.21 | $30.63 | +0.00% |
| June 2026 | $22.22 | $25.92 | $30.83 | -1.09% |
| July 2026 | $22.49 | $26.38 | $31.67 | +1.77% |
| August 2026 | $22.89 | $26.97 | $32.61 | +2.23% |
| September 2026 | $22.60 | $26.74 | $32.52 | -0.86% |
| October 2026 | $22.57 | $26.79 | $32.76 | +0.18% |
| November 2026 | $23.33 | $27.78 | $34.13 | +3.70% |
| December 2026 | $23.81 | $28.43 | $35.08 | +2.34% |
Click any year to see its month-by-month PFE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PFE to range from $25.15 to $35.08 through 2026. The $26.21 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PFE price prediction for 2027 points to an average of $31.85 (low $26.02, high $40.81) — a potential gain of +22% on today's $26.21. Buyers look set to stay in control over this stretch.
In 2028, PFE is projected to trade between $31.50 and $51.62, averaging $39.26 — a potential gain of +50% from today's $26.21. That is up +23% on the projected 2027 average. Momentum favours further upside here.
Pfizer Inc.'s 2029 outlook centres on $43.05, within a $34.03 to $57.78 range. That is up +10% on the projected 2028 average. That marks a +64% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, PFE could reach as high as $60.88, with a base case around $44.57 and support toward $34.76 — roughly +70% from $26.21. Momentum favours further upside here.
Expect PFE to range from $38.65 to $69.58 through 2031. The $50.16 average target implies a +91% move from current prices. That is up +13% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The PFE price prediction for 2032 points to an average of $51.46 (low $39.21, high $72.38) — a potential gain of +96% on today's $26.21. Momentum favours further upside here.
In 2033, PFE is projected to trade between $40.71 and $76.91, averaging $53.98 — a potential gain of +106% from today's $26.21. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Pfizer Inc.'s 2034 outlook centres on $65.34, within a $48.80 to $94.19 range. That is up +21% on the projected 2033 average. That marks a +149% change versus current levels. Momentum favours further upside here.
By 2035, PFE could reach as high as $106.94, with a base case around $73.38 and support toward $54.29 — roughly +180% from $26.21. Buyers look set to stay in control over this stretch.
Expect PFE to range from $68.03 to $146.41 through 2040. The $95.89 average target implies a +266% move from current prices. That is up +31% on the projected 2035 average. Momentum favours further upside here.
The PFE price prediction for 2050 points to an average of $197.87 (low $130.92, high $323.77) — a potential gain of +655% on today's $26.21. Buyers look set to stay in control over this stretch.
Investing $1,000 in PFE today (≈ 38.153377 PFE) could be worth
$7,549.47
+$6,549.47 (+655%) by 2050 · US Dollar
Based on the average projected PFE price of $197.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PFEwould be worth at today's price.
$1,000 invested in PFE on May 27, 2025 (≈ 42.354933 PFE) would be worth
$1,110.12
+$110.12 (+11.0%) today · 1.11× · US Dollar
Based on a PFE entry price of $23.61 vs. today's $26.21.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $25.79 | $1,016.29 | +1.6% |
| 1 month ago | $26.79 | $978.35 | -2.2% |
| 3 months ago | $27.1 | $967.16 | -3.3% |
| 6 months ago | $25.74 | $1,018.26 | +1.8% |
| 1 year ago | $23.61 | $1,110.12 | +11.0% |
| All time (5.0y) ago | $38.5 | $680.78 | -31.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PFE forecast.
Our base-case forecast reaches $52.00 around 2033.
Implied market cap at $52.00: $296.37B
Looking out over the multi-year horizon, the forecast shows a clear path of higher averages. In 2027 the avg is $31.78, rising to $39.29 in 2028, then $42.98 in 2029, and $44.69 in 2030, with corresponding ROIs of 22.7%, 51.7%, 65.9%, and 72.5% respectively and bullish sentiment.
Further out, 2040 carries an avg of $97.99 with an ROI of 278.3% and 2050 an avg of $201.70 with an ROI of 678.8%, both labeled as bullish.
Across these horizons, the sentiment remains bullish as averages climb, but these figures are estimates, not guarantees. Investors should consider the inherent uncertainty and use these projections as one input among others.
Tap a question to reveal the answer.
The forecast shows a 2030 average price of $44.69, with a min of $34.85 and a max of $61.05, and an ROI of 72.5%. The sentiment for 2030 is BULLISH.
Near-term by 2026 the average is $25.90 (neutral), while the longer horizon shows bullish upside with 2027–2050 averages trending higher and ROIs reaching up to 678.8% by 2050.
Yes. The 2040 average is $97.99 and the 2050 average is $201.70, indicating the potential to surpass $100 by the 2050 horizon.
The current price is $25.90.
The 30-day range is $24.36 to $27.54. Current price $25.90 sits between support $25.33 and resistance $27.56. SMA50 is $26.81, SMA200 is $25.80, RSI14 is 40, and the sentiment is BULLISH with 20% annualized volatility.
Pfizer Inc. Community Discussion
0Share your Pfizer Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.